HT BioImaging is a privately held Israeli based company, founded in 2015 and is dedicated to the development and commercialization of a proprietary, advanced cancer detection technology.
Early detection of cancer is vital for improving survival rate of cancer patients. Currently, early detection mostly takes place at the hospital, using imaging modalities and implementing an array of technologies - from harmless ultrasound to highly radiative CT and PET scans. The General Practitioner has almost no tools available at the outpatient clinic for point of care diagnosis, other than the analysis of symptoms and signs presented by the patient and blood tests. Results of blood and cytological tests performed, require a couple of days and up to several weeks, for the availability of final results.
Patients who are showing suspicious symptoms, mostly experience anxiety during the period of waiting for conclusive results, resulting in denial, and ignoring the need for radiative examination. This is most obvious in the early onsets of the symptoms.
The HT BioImaging system utilizes smart algorithms to create a new imaging methodology that will be used to detect many types of malignancies that currently do not have early detection procedures and improving on existing, problematic screening methods.
HT BioImaging has completed a First-In-Human study to assess the sensitivity, specificity, false-positive and false-negative of a functional based imaging system in identifying normal tissue, abnormal tissue, and cancerous tissue in humans.
The study was approved by the ‘Israeli ministry of health’ IRB to test adult patients with an oral suspicious lesion in Sheba Medical Center and Assaf Harofe, Israel.
This clinical trial demonstrated the effectiveness of using the HT BioImaging System, a portable, easy to use and short learning curve system, as a clinical diagnostic aid with over 90% sensitivity and specificity in the detection of normal vs. abnormal lesions of the oral cavity.
Meet The Team
Co-Founder & CEO
B.Sc. in Mechanical Engineering specialized in heat transfer and thermodynamics. Shani has over 11 years of experience in the tech, defense & aviation industry as a developer, system engineer, and R&D team leader.
Co-Founder & Chairman
Gideon is a serial entrepreneur with 10-exits record. He held leading positions in several companies including co-founder and CEO of DSP Communications (NASDAQ: DSPC), acquired by Intel in 1999 for $1.6 billion, and Founder and Chairman of Envara and Butterfly VLSI, acquired by Intel and Texas Instruments in 2004 and 2000, respectively.
Dr. Gabriel Polliack
MD MHA CMO
Dr. Sharon Gat
Dr. Moshe Tshuva
Dr. Amir Onn
Dr. Michael Glick
Dr. Joseph Katz
Dr. Allen Finkelstein